Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
1.
Fukuoka Igaku Zasshi ; 101(10): 215-24, 2010 Oct.
Article in English | MEDLINE | ID: mdl-21375144

ABSTRACT

To clarify the prevalence and incidence of diabetes and to evaluate which risk factors are predictive of future diabetes in the general population of Okinawa, 1,690 residents were screened in 1989 and 758 were prospectively followed-up in 1999. Of the 1,690 residents surveyed in 1989 and 1, 163 in 1999, diabetes was found in 91 (5.4%) in 1989 and 52 (4.5%) in 1999. Residents with diabetes were significantly older, more likely to have significantly higher levels of HbA1c, fasting glucose, serum triglyceride, ALT, BMI, systolic blood pressure, and a history of hypertension than non diabetic residents, both in 1989 and 1999. 717 residents who did not have diabetes at the 1989 screening were re-examined in 1999. Among them, 17 (incidence rate 2.4%) had developed diabetes over the ten years. Multivariate logistic regression analysis showed HbA1c, BMI, and systolic blood pressure to be independent risk factors for newly developed diabetes (p < 0.0001, odds ratio; 28.1, p = 0.020, odds ratio; 1.21, p = 0.039, odds ratio; 1.04, respectively) after adjusting for age, sex, BMI, blood pressure, hystory of hypertension, HbA1c, fasting glucose, serum triglyceride, ALT, and y GTP. Our results showed that the prevalence and incidence of diabetes are low in the general population of the Yaeyama district of Okinawa and that elevated HbA1c level, even in the normal range, is one of the best predictors of diabetes. Following BMI and systolic blood pressure is important.


Subject(s)
Diabetes Mellitus/epidemiology , Adult , Aged , Aged, 80 and over , Diabetes Mellitus/etiology , Female , Humans , Japan/epidemiology , Male , Middle Aged , Prevalence , Risk Factors
2.
J Infect Chemother ; 14(6): 418-23, 2008 Dec.
Article in English | MEDLINE | ID: mdl-19089555

ABSTRACT

An outbreak of Pseudomonas aeruginosa infections occurred after thoracic surgeries performed between May and June 2003. Clinical data of seven patients were reviewed and the fact was revealed that bronchoscopes were used during endotracheal intubation for one-lung ventilation in most patients. P. aeruginosa was recovered from the sputum of these patients at a very early stage post-operation. Environmental samples from bronchoscopes and an automated endoscope reprocessor (AER) were cultured and P. aeruginosa strains were recovered from all of them. All of these strains were confirmed to be identical by pulsed-field gel electrophoresis (PFGE). Inspection of the sterilization cycles of bronchoscopes revealed inappropriate management of bronchoscopes and a flaw in the AER; once its detergent tank was contaminated, it was not possible to disinfect it. After all the bronchoscopes had been disinfected, and the washing machine had been remodeled, with the washing process confirmed to be appropriate, the outbreak finally ended. This outbreak had two causes, a flaw in the AER and inappropriate disinfection procedures. Outbreaks associated with bronchoscopic examinations have been reported elsewhere. Bronchoscopes are widely used to facilitate endotracheal intubation, especially for one-lung anesthesia. Although they are used for only a short time during anesthetic procedures, we should handle them more carefully.


Subject(s)
Bronchoscopes/microbiology , Cross Infection/epidemiology , Disease Outbreaks , Equipment Contamination , Pseudomonas Infections/epidemiology , Pseudomonas aeruginosa/isolation & purification , Thoracic Surgical Procedures , Adult , Aged , Cross Infection/microbiology , Endoscopes/microbiology , Equipment Reuse , Female , Humans , Male , Middle Aged , Pseudomonas Infections/microbiology , Pseudomonas aeruginosa/classification , Pseudomonas aeruginosa/genetics , Sputum/microbiology , Sterilization/instrumentation , Sterilization/methods , Thoracic Surgical Procedures/adverse effects , Thoracic Surgical Procedures/instrumentation , Thoracic Surgical Procedures/methods , Young Adult
3.
J Clin Endocrinol Metab ; 93(5): 1884-92, 2008 May.
Article in English | MEDLINE | ID: mdl-18319322

ABSTRACT

CONTEXT: All-trans retinoic acid (tRA) induces differentiation in MCF-7 breast cancer cells, stimulates sodium/iodide symporter (NIS) gene expression, and inhibits cell proliferation. Radioiodine administration after systemic tRA treatment has been proposed as an approach to image and treat some differentiated breast cancer. OBJECTIVE: The objective of this work was to study the relative role of genomic and nongenomic pathways in tRA stimulation of NIS expression in MCF-7 cells. DESIGN: We inspected the human NIS gene locus for retinoic acid-responsive elements and tested them for function. The effects of signal transduction pathway inhibitors were also tested in tRA-treated MCF-7 cells and TSH-stimulated FRTL-5 rat thyroid cells, followed by iodide uptake assay, quantitative RT-PCR of NIS, and cell cycle phase analysis. RESULTS: Multiple retinoic acid response elements around the NIS locus were identified by sequence inspection, but none of them was a functional tRA-induced element in MCF-7 cells. Inhibitors of the IGF-I receptor, Janus kinase, and phosphatidylinositol 3-kinase (PI3K), significantly reduced NIS mRNA expression and iodide uptake in tRA-stimulated MCF-7 cells but not FRTL-5 cells. An inhibitor of p38 MAPK significantly reduced iodide uptake in both tRA-stimulated MCF-7 cells and TSH-stimulated FRTL-5 cells. IGF-I and PI3K inhibitors did not significantly reduce the basal NIS mRNA expression in MCF-7 cells. Despite the chronic inhibitory effects on cell proliferation, tRA did not reduce the S-phase distribution of MCF-7 cells during the period of NIS induction. CONCLUSION: The IGF-I receptor/PI3K pathway mediates tRA-stimulated NIS expression in MCF-7 but not FRTL-5 thyroid cells.


Subject(s)
Breast Neoplasms/metabolism , Insulin-Like Growth Factor I/physiology , Phosphatidylinositol 3-Kinases/physiology , Signal Transduction/physiology , Symporters/genetics , Tretinoin/pharmacology , p38 Mitogen-Activated Protein Kinases/physiology , Breast Neoplasms/pathology , Cell Line, Tumor , Cell Proliferation/drug effects , Chromones/pharmacology , Cyclic AMP-Dependent Protein Kinases/physiology , Female , Humans , MAP Kinase Signaling System , Morpholines/pharmacology , Phosphoinositide-3 Kinase Inhibitors , Protein Kinase C/physiology , Tyrphostins/pharmacology
4.
J Med Virol ; 79(3): 320-5, 2007 Mar.
Article in English | MEDLINE | ID: mdl-17245715

ABSTRACT

Fifty seven hospital workers received influenza vaccine in November 2003, and the serum HI antibody titer was determined before, 2 and 4 weeks after the vaccination. Thirty seven were vaccinated in November, 2002 consecutively (the repeated vaccination group), and the remaining 20 had not been vaccinated in the previous year (the single vaccination group). Six of the repeated vaccination group received both influenza and hepatitis B vaccination in September, 2004 and the antibody responses were examined 2 weeks later. Two and four weeks after the 2003-vaccination, the HI antibody titers to A/H1N1, A/H3N2, and B in the repeated vaccination group were significantly lower than in the single vaccination group (P < 0.05). This phenomenon had no relation to the pre-vaccination HI antibody titer. The antibody response was low to repeated influenza vaccination, but normal to hepatitis B vaccine in six subjects who had a second vaccination in 2004, showing that this depressed response was influenza-specific. These results suggest that the decreased HI antibody response to repeated influenza vaccination was affected mainly by the previous vaccination per se rather than by the pre-existing antibody titer.


Subject(s)
Antibodies, Viral/blood , Immunization, Secondary , Influenza A virus/immunology , Influenza B virus/immunology , Influenza Vaccines/immunology , Adult , Hemagglutination Inhibition Tests , Hepatitis B Antibodies/blood , Hepatitis B Vaccines/immunology , Humans , Influenza A Virus, H1N1 Subtype/immunology , Influenza A Virus, H3N2 Subtype/immunology , Middle Aged
5.
Endocrinology ; 146(7): 3059-69, 2005 Jul.
Article in English | MEDLINE | ID: mdl-15817668

ABSTRACT

The sodium/iodide symporter (NIS) mediates iodide uptake in lactating breast tissue and is expressed in some breast cancers. We have previously demonstrated that all-trans retinoic acid (tRA) stimulates NIS gene expression and the selective cytotoxic effect of beta-emitting radioiodide-131 ((131)I) in both in vitro and in vivo MCF-7 breast cancer cell systems. We studied the ability of natural and synthetic retinoids, in combination with other nuclear receptor ligands, to achieve greater and more sustained induction of NIS in MCF-7 cells and enhance (131)I-mediated cytotoxicity. Selective stimulation of retinoic acid receptor (RAR) beta/gamma produced marked NIS induction; and selective stimulation of RARalpha, RARgamma, or retinoid X receptor produced more modest induction. Maximal NIS induction was seen with 9-cis retinoic acid and AGN190168, a RAR beta/gamma-agonist. Dexamethasone (Dex), but not the other nuclear receptor ligands, in combination with tRA synergistically induced iodide uptake and NIS mRNA expression, predominantly by prolonging NIS mRNA half-life. The addition of Dex reduced the EC(50) of tRA for NIS stimulation to approximately 7%, such that 10(-7) m tRA with addition of Dex enhanced iodide uptake and selective cytotoxicity of (131)I greater than 10(-6) m tRA alone. AGN190168 combined with Dex synergistically increased iodide uptake and significantly prolonged induction (5 d) of iodide uptake compared with that induced by the combination of tRA/Dex or 9-cis retinoic acid/Dex. The addition of Dex reduced the effective dose of retinoid and prolonged the induction of NIS, especially with AGN190168, suggesting higher efficacy of (131)I after combination treatment.


Subject(s)
Breast Neoplasms/metabolism , Receptors, Cytoplasmic and Nuclear/metabolism , Symporters/metabolism , Antineoplastic Agents/pharmacology , Antineoplastic Agents, Hormonal/administration & dosage , Antineoplastic Agents, Hormonal/pharmacology , Breast Neoplasms/genetics , Breast Neoplasms/pathology , Cell Line, Tumor , Dexamethasone/administration & dosage , Dexamethasone/pharmacology , Drug Administration Schedule , Drug Combinations , Female , Gene Expression/drug effects , Glucocorticoids/administration & dosage , Glucocorticoids/pharmacology , Humans , Iodides/pharmacokinetics , Iodine Radioisotopes/pharmacology , Ligands , RNA, Messenger/metabolism , Retinoids/administration & dosage , Retinoids/metabolism , Retinoids/pharmacology , Symporters/genetics , Tretinoin/pharmacology , Tumor Stem Cell Assay
6.
Cancer Res ; 64(1): 415-22, 2004 Jan 01.
Article in English | MEDLINE | ID: mdl-14729653

ABSTRACT

Lactating breast tissue and some breast cancers express the sodium/iodide symporter (NIS) and concentrate iodide. We recently demonstrated that all-trans retinoic acid (tRA) induces both NIS gene expression and iodide accumulation in vitro in well-differentiated human breast cancer cells (MCF-7). In the present study, we investigated the in vivo efficacy and specificity of tRA-stimulated iodide accumulation in mouse breast cancer models. Immunodeficient mice with MCF-7 xenograft tumors were treated with systemic tRA for 5 days. Iodide accumulation in the xenograft tumors was markedly increased, approximately 15-fold greater than levels without treatment, and the effects were tRA dose dependent. Iodide accumulation in other organs was not significantly influenced by tRA treatment. Significant induction of NIS mRNA and protein in the xenograft tumors was observed after tRA treatment. Iodide accumulation and NIS mRNA expression were also selectively induced in breast cancer tissues in transgenic mice expressing the oncogene, polyoma virus middle T antigen. These data demonstrate selective induction of functional NIS in breast cancer by tRA. Treatment with short-term systemic retinoic acid, followed by radioiodide administration, is a potential tool in the diagnosis and treatment of some differentiated breast cancer.


Subject(s)
Breast Neoplasms/drug therapy , Iodine Radioisotopes/pharmacokinetics , Symporters/genetics , Tretinoin/pharmacology , Animals , Breast Neoplasms/diagnostic imaging , Breast Neoplasms/pathology , Cell Line, Tumor , Female , Gene Expression Regulation, Neoplastic , Humans , Mice , Mice, SCID , Radionuclide Imaging , Symporters/drug effects , Symporters/radiation effects , Tissue Distribution , Transplantation, Heterologous
7.
Breast Cancer Res Treat ; 78(1): 119-26, 2003 Mar.
Article in English | MEDLINE | ID: mdl-12611464

ABSTRACT

Luciferase genes are widely used as reporters to analyze promoter and regulatory elements. We found that a luciferase reporter gene vector with a modified firefly luciferase gene (luc+), but not Renilla luciferase (Rluc), was induced by all-trans retinoic acid (tRA) in the MCF-7 breast cancer cell line. tRA (5 x 10(-6) M) increased luciferase activity of the pGL3 promoter vector (containing luc+) up to approximately 3.8-fold in MCF-7 cells, but not in LNCaP prostate cancer cells or JEG-3 choriocarcinoma cells. Chimeric plasmids were constructed and showed that tRA-induction required the luc+ gene, but not any specific promoter or vector sequence. Time course and dose-response studies of tRA-induction indicated that longer treatment (> 24h) and higher tRA dose (> 10(-6) M) were required for luc+ induction compared with those for a positive retinoic acid response element (maximum induction at 6 h and 10(-8) M tRA). Studies with the translation inhibitor, cycloheximide, indicated the half-life of the luc+ protein was increased from 9.7 +/- 1.5 to 22.1 +/- 3.1 h with tRA treatment. Other retinoids, TTNPB, a retinoic acid receptor beta/gamma-specific ligand, and a retinoid X receptor ligand, did not significantly increase luc+ expression. Caution is needed in analysis of retinoid responsive gene regulation with the luciferase reporter system in MCF-7 cells, especially at high retinoid concentrations.


Subject(s)
Breast Neoplasms/genetics , Gene Expression Regulation, Neoplastic/drug effects , Genes, Reporter/drug effects , Genes, Reporter/genetics , Luciferases/drug effects , Luciferases/genetics , Tretinoin/pharmacology , Animals , Coleoptera , Dose-Response Relationship, Drug , Female , Genetic Vectors , Humans , Tretinoin/physiology , Tumor Cells, Cultured
8.
Mol Endocrinol ; 16(10): 2266-82, 2002 Oct.
Article in English | MEDLINE | ID: mdl-12351692

ABSTRACT

The sodium/iodide symporter (NIS) gene is highly expressed in the thyroid gland and is important for the diagnosis and radioiodide therapy of differentiated thyroid cancers. We investigated a human NIS (hNIS) gene 5'-far-upstream enhancer (hNUE) (-9847 to -8968). The hNUE is TSH responsive in both FRTL-5 cells and primary normal thyroid cells, but not in human papillary thyroid cancer cells (BHP cells). The hNUE enhanced expression of the basal hNIS promoter 15-fold and required both a Pax-8 binding site and a cAMP response element (CRE)-like sequence for full activity. The hNUE activated transcription in a thyroid-selective and cAMP-dependent manner, mediated by both protein kinase A (PKA)-dependent and PKA-independent pathways. Pax-8 and two CRE-like sequence binding proteins bind to the hNUE. Supershift binding assay indicated that one of the CRE-like sequence binding protein(s) was CRE-binding protein-1, activation transcription factor-1, and/or CRE modulator, and the other was an unknown factor(s) that is absent in BHP 2-7 cells. A far-upstream enhancer is important for hNIS regulation in the thyroid. Deficient CRE-like sequence binding protein(s) that bind to the hNUE in normal thyroid cells may be responsible for reduced NIS gene expression in some thyroid carcinomas.


Subject(s)
Carcinoma, Papillary/genetics , DNA-Binding Proteins/metabolism , Enhancer Elements, Genetic , Symporters/genetics , Symporters/metabolism , Thyroid Gland/physiology , Thyroid Neoplasms/genetics , Trans-Activators/metabolism , Activating Transcription Factor 2 , Animals , Binding Sites , Carcinoma, Papillary/metabolism , Cell Differentiation/genetics , Cells, Cultured , Cyclic AMP/metabolism , Cyclic AMP Response Element-Binding Protein/genetics , Cyclic AMP Response Element-Binding Protein/metabolism , Cyclic AMP-Dependent Protein Kinases/metabolism , DNA-Binding Proteins/genetics , Gene Expression Regulation , Humans , Mutation , Nuclear Proteins/genetics , Nuclear Proteins/metabolism , PAX8 Transcription Factor , Paired Box Transcription Factors , Promoter Regions, Genetic , Rats , Reference Values , Response Elements/genetics , Sequence Homology, Nucleic Acid , Symporters/drug effects , Thyroid Gland/cytology , Thyroid Neoplasms/metabolism , Thyroid Nuclear Factor 1 , Trans-Activators/genetics , Transcription Factors/genetics , Transcription Factors/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...